Glutamatergic transmission: Therapeutic prospects for schizophrenia and alzheimer’s disease

Nuri B. Farber, John W. Newcomer, John W. Olney

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

Extensive research focusing on the amino acid, glutamate (Glu), has documented the central role played by this compound in both the normal and abnormal functioning of the central nervous system (CNS). Glu is now recognized to be the main excitatory neurotransmitter in the CNS, estimated to be released at up to half of the synapses in the brain. In addition, Glu is also an excitotoxin that can destroy CNS neurons by excessive activation of excitatory receptors on dendritic and somal surfaces.

Original languageEnglish
Title of host publicationGlutamate and GABA Receptors and Transporters
Subtitle of host publicationStructure, Function and Pharmacology
PublisherCRC Press
Pages385-406
Number of pages22
ISBN (Electronic)9780203299388
ISBN (Print)9780748408818
StatePublished - Jan 1 2001

Fingerprint Dive into the research topics of 'Glutamatergic transmission: Therapeutic prospects for schizophrenia and alzheimer’s disease'. Together they form a unique fingerprint.

  • Cite this

    Farber, N. B., Newcomer, J. W., & Olney, J. W. (2001). Glutamatergic transmission: Therapeutic prospects for schizophrenia and alzheimer’s disease. In Glutamate and GABA Receptors and Transporters: Structure, Function and Pharmacology (pp. 385-406). CRC Press.